Generation and Quantitative Analysis of Pulsed Low Frequency Ultrasound to Determine the Sonic Sensitivity of Untreated and Treated Neoplastic Cells.
Low frequency ultrasound in the 20 to 60 kHz range is a novel physical modality by which to induce selective cell lysis and death in neoplastic cells. In addition, this method can be used in combination with specialized agents known as sonosensitizers to increase the extent of preferential damage exerted by ultrasound against neoplastic cells, an approach referred to as sonodynamic therapy (SDT). The methodology for generating and applying low frequency ultrasound in a preclinical in vitro setting is presented to demonstrate that reproducible cell destruction can be attained in order to examine and compare the effects of sonication on neoplastic and normal cells. This offers a means by which to reliably sonicate neoplastic cells at a level of consistency required for preclinical therapeutic assessment. In addition, the effects of cholesterol-depleting and cytoskeletal-directed agents on potentiating ultrasonic sensitivity in neoplastic cells are discussed in order to elaborate on mechanisms of action conducive to sonochemotherapeutic approaches.
Department of Biology, Syracuse University; mrtrendo@syr.edu.
Matthew
M
Trendowski
Department of Biology, Syracuse University.
Timothy D
TD
Christen
Department of Biology, Syracuse University.
Joseph N
JN
Zoino
Department of Biology, Syracuse University.
Christopher
C
Acquafondata
Department of Biology, Syracuse University.
Thomas P
TP
Fondy
D000970:Antineoplastic Agents / Q000494:pharmacology*; D016923:Cell Death / Q000187:drug effects; D003131:Combined Modality Therapy; D003599:Cytoskeleton / Q000187:drug effects; D006801:Humans; D007951:Leukemia, Myeloid / Q000000981:diagnostic imaging / Q000188:drug therapy / Q000628:therapy*; D013010:Sonication / Q000295:instrumentation / Q000379:methods*; D020298:U937 Cells; D014464:Ultrasonic Therapy / Q000295:instrumentation / Q000379:methods*; D014463:Ultrasonography; D047392:beta-Cyclodextrins / Q000494:pharmacology
D000970:Antineoplastic Agents; D047392:beta-Cyclodextrins; C108732:methyl-beta-cyclodextrin